All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-05-05T16:37:54.000Z

NICE recommend long-term funding for brentuximab vedotin for adult patients with CD30+ relapsed/refractory Hodgkin Lymphoma

May 5, 2017
Share:

Bookmark this article

Last month, the National Institute for Health and Care Excellence (NICE) published a final appraisal recommending long-term funding for Adcetris® (brentuximab vedotin) as an option for adult patients with CD30+ R/R Hodgkin Lymphoma (HL) following an ASCT;1 a complete change of heart from their draft guidelines published last year.

Back in December 2016, NICE published draft guidelines rejecting use of ADCETRIS®, despite new evidence and a drop in price, due to “uncertainties” in the evidence.2

However, in the final appraisal, the recommended long-term funding will be made available for ADCETRIS® as long as Takeda continues to provide the drug at the price agreed with NHS England in the commercial access agreement.

In addition, NICE has recommended funding via the Cancer Drugs Fund (CDF) for adult patients with CD30+ R/R HL following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, if the conditions of the managed access agreement are followed.

Takeda’s ADCETRIS® is currently approved by the European Medicines Agency (EMA) to treat patients with R/R CD30+ Hodgkin Lymphoma after ASCT or after at least 2 previous therapies when ASCT or multi-agent chemotherapy is not a treatment option, and in patients who are at an increased risk of relapse or progression after ASCT. ADCETRIS® is also indicted by the EMA for patients with R/R sALCL.

  1. PharmaTimes. NICE u-turn recommends some access to Takeda’s Adcetris. 2017 Apr 28. http://www.pharmatimes.com/news/nice_u-turn_recommends_some_access_to_takedas_adcetris_1192062. [Accessed 2017 May 02].
  2. PharmaTimes. NICE bars Adcetris from routine NHS use for Hodgkin’s lymphoma. 2016 Dec 16. http://www.pharmatimes.com/news/nice_bars_adcetris_from_routine_nhs_use_for_hodgkins_lymphoma_1182093. [Accessed 2017 May 02].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox